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ABSTRACT 
Genistein, an isoflavone, specifically inhibits protein tyrosine kinases (PTK). In 
low concentrations, genistein enhances natural killer (NK) cell lytic activity of 
peripheral blood leukocytes (PBL) in a dose dependent manner. The following study 
was designed to investigate if the enhancement of lytic activity was associated with 
the modulation of PTK's by genistein. A flow cytometric assay was developed to 
monitor phosphorylation of intracellular tyrosine residues in a pure population of NK 
cells (NK 3.3) in parallel with a chromium release assay for lytic activity. The flow 
cytometric assay used an anti- phosphotyrosine-FITC conjugated antibody in 
conjunction with the phosphatase inhibitor, pervanadate. Genistein at 
concentrations of 0.1-10 uM was found to inhibit baseline phosphorylation and 
phosphorylation in the presence of pervanadate of activated NK3.3 cells. However, 
while tyrosine phosphorylation was inhibited, the lytic ability of NK 3.3 cells against 
K562 cells was not affected and showed a slight enhancement of lytic activity. 
Genistien was observed to enchance the lytic ability of rested NK3.3 cells as well as 
a corresponding enhancement of intracellular phosphotyrosine residues. Since 
tyrosine phosphorylation provides an early and requisite signal for NK cell lytic 
activity, these results suggest that another pathway (non-phosphotyrosine) is utilized 
during activation of lytic activity. Thus, genistein does not appear to enhance lytic 
activity of NK 3.3 cells by modulation of their PTK's. 
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INTRODUCTION 
The lower incidence of breast, colon, and prostate cancer in Asian countries 
brought attention to the differences in diet between Asian and Western cultures, 
particularly the consumption of soy-containing foods (36). The anti-cancer effects 
are thought to be due to isoflavones in soy, principally genistein. Use of in vivo 
(animal) models, demonstrate that soy products containing genistein in the diet 
significantly reduce the risk of cancer. Use of in vitro models, demonstrate that 
genistein inhibits the proliferation of human tumor cell lines (5). Previous in vitro 
studies in our lab demonstrated enhancement of lytic activity of harvested human 
NK cells against human tumor cells in the presence of low concentrations of 
genistein (< 1 µM). These effects may be related to regulation of NK cells that are 
involved in killing tumor cells and virally transformed cells. 
Tyrosine phosphorylation has been found to be an early and necessary signal for 
lytic activity in natural killer (NK) cells (20). Genistein, an isoflavone, is a specific 
inhibitor of protein tyrosine kinases (PTKs) and can be used as a tool for 
understanding the role PTKs play in the activation of cytotoxicity (2). Previous 
studies have shown that genistein (10 µg/ml or 37 µM) inhibits the src protein 
tyrosine kinase p561ck in "NK-rich" cells exposed to IL-2 with a resultant decrease in 
cytotoxic activity against K562 cells (39). Thus, biological studies have shown that 
genistein can enhance or inhibit NK cytotoxicity depending on the assay conditions 
used. 
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The purpose of this research was to ask if low concentrations of genistein had a 
direct effect on natural killer cell lytic activity and if the observed cytobiological 
effects of genistein were related to changes in signal transduction, particularly 
protein tyrosine kinases (PTKs). Initial studies used NK cells harvested from 
peripheral blood leukocytes. When it was observed that genistein had an effect on 
lytic activity, a pure NK cell line was to study the direct results of genistein on NK 
cells. The NK3.3 cell line was used as a model system so that a pure population of 
natural killer ceUs would define direct results of genistein on those cells. Intracellular 
levels of phosphorylated tyros:ine residues after treatment with low doses of 
genistein were examined by flow cytometry (21, 24). Lytic activity was assayed in 
parallel by a chromium release assay (12). Together these studies attempt to define 
a relationship between enhanced lytic function and intracellular tyrosine 
phosphorylation due to genistein. 
Innate Immunity 
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LITERATURE REVIEW 
The immune system is divided into two branches. There is acquired (adaptive) 
immunity that specifically recognizes and eliminates that which is foreign. The 
second branch is innate (natural) immunity, which is the basic resistance to disease 
one is born with. Contrary to some beliefs, the innate immune system is not some 
left over relic from evolution nor is it the "containment crew" until adaptive immunity 
"kicks in". Rather adaptive immunity owes its existence to innate immunity. Innate 
immunity is composed of anatomic barriers, phagocytic cells, complement, and 
natural killer cells. The last three components of the innate immune system generate 
signals that activate and even direct the type of effector response of acquired 
immunity (35, 46). 
Neutrophils and macrophages are two key phagocytic cells of innate immunity. 
Inflammation is the hallmark of an innate immune response and it also activates 
neutrophils and macrophages (46). Neutrophils are the most numerous of 
granulocytes found in the blood. Macrophages are derived from monocytes 
circulating in the blood that migrate into tissue and become tissue specific 
macrophages (28). Both cell types recognize conserved structures found on 
microbes called PAMPS for pathogen-associated molecular patterns and 
components of the complement system (35, 46). In addition, both have complement 
receptors and Fe receptors in order to recognize organisms covered with C3b, an 
active fragment of complement component C3 or antibody, a process called 
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opsonization. Neutrophils and macrophages engulf microbes. The granules of 
neutrophils contain lytic enzymes and bactericidal substances that fuse with a 
phagosome to digest infectious material (28). Neutrophil granules also induce the 
release of biological response modifiers, cytokines and chemokines, by 
macrophages (46). Macrophages, after internalizing infectious material, destroy 
them by the creation of a phagolysosome that contains hydrogen peroxide, 
peroxidase, lysozyme, and other hydrolytic enzymes, which digest the material. The 
digestive fragments (antigens) are brought to the surface of the macrophage where 
they can be presented to T-cells (28, 47). Macrophages binding to infectious 
material also stimulate the release of cytokines and chemokines. 
Cytokines released by phagocytic cells are able to activate the complement 
cascade. Complement is a group of serum proteins involved in inflammation, 
activation of macrophages, and participates in an enzymatic cascade that 
culminates in lysis of cell membranes (47). Complement and phagocytic cells have 
a symbiotic relationship. Complement activation induces chemotaxis and 
opsonization, which generates the participation of macrophages. Macrophages 
produce cytokines that stimulate the liver to produce acute phase proteins, C-
reactive protein and mannan-binding lectin (MBP) that activate complement by 
different pathways. C-reactive protein does this by binding to and activating 
complement component one, much like the initiation of the classic pathway by 
antibody binding. MBP recognizes and binds to mannose found on bacterial cell 
walls to activate complement by the lectin pathway. This reaction substitutes for the 
activation of the first component of complement. 
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Phagocytic cells and complement are efficient for dealing with extracellular 
bacterial infections but they cannot reach pathogens (viruses as an example) that 
reside inside of cells. Natural killer cells have the intrinsic ability to lyse virally 
infected cells and tumor cells particularly hemopoietic tumors. NK cells play a role in 
innate immunity as effector cells and a source of cytokines that modulate other 
immune cell activities (45). 
Natural Killer Cells 
Natural killer (NK) cells can be found in earthworms, sharks, common fish, 
amphibians, reptiles, birds, and mammals. In humans, NK cells are the third major 
class of lymphocytes and comprise 10 -15% of the lymphocyte population in the 
blood, liver, and especially in the spleen (red pulp), but are rarely found in lymph 
nodes. NK cells are thymic independent, do not undergo immunoglobulin (lg) or T 
cell receptor (TCR) gene rearrangement, have no classic antigen binding receptors, 
and no CD3. NK cells have non-specific cytotoxicity and do not require antigenic 
stimulation or MHC class restricted presentation of antigen. The developmental 
lineage of NK cells is unknown, however there are two theories as to their origins. 
One is that NK cells develop from a distinct lineage from that of T-cells (since SCIO 
mice who have no T-cells still have NK cells) or second, both NK·and T cells 
originate from the same early progenitor cell before rearrangement of TCR genes 
since NK cells do share some markers with T-cells. Morphologically, NK cells are 
referred to as large granular lymphoctyes (LGL) due to having a high cytoplasm to 
nucleus ratio, a kidney shaped nucleus, and large azurophilic granules (28). NK cells 
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can be activated (to kill targets) by cytokines or cell-to-cell contact (44). Definitive 
cell surface markers for NK cells are CD16 and CD56. CD16 is a FcyRIII receptor 
found as a Type I transmembrane protein on NK cells. CD16 belongs to the lg 
superfamily and mediates binding to lgG coated particles. CD56 also is a Type I 
transmembrane protein, member of the lg superfamily, and is an isoform of N-CAM 
(neural cell adhesion molecule) called a hemophilic adhesion molecule. CO2 (LFA-2) 
is another marker found on the NK cell surface. CO2 is also found on T-cells and is 
sometimes called the E-rossette receptor. It is a Type I transmembrane protein of 
the lg superfamily, an adhesion molecule whose ligand is CD58 that is found on 
many cell types. In the case of T-cells, CO2 serves as an accessory molecule to 
promote binding of cytotoxic T-cells to their targets (23). CD57, also known as HNK-
1, is an oligosaccharide present on NK cells with no known function. NK cells 
express the and y signal transducing subunits of the IL-2 receptor but not the a 
subunit required for high affinity binding of IL-2 to the receptor. When expressed, IL-
2Ra reduces the amount of IL-2 needed for activation and growth. Since there is no 
IL-2Ra expressed after stimulation with IL-2, NK cells, unlike T cells when activated 
with IL-2, cannot reduce the amount of IL-2 needed to maintain activation (1). 
When stimulated by high concentrations of IL-2, NK cells proliferate and lytic 
activity is enhanced. This enhancement is a consequence of IL-2 activation to 
transform NK cells to lymphokine activated killer (LAK) cells. LAK cells have 
enhanced cytotoxic ability and a broader range of target specificity. This means that 
LAK cells, unlike NK cells, can kill a wider variety of tumor cells and even normal cell 
types like epithelial cells. 
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There are two pathways that NK cells utilize for cytolytic activity: antibody 
dependent cellular cytotoxicity (ADCC) by CD16 and direct cell-mediated 
cytotoxicity. With ADCC, the target cell is coated with specific lgG to which the low 
affinity Fey receptor, CD16, binds. This binding engages the pathway to lytic activity 
while also activating NK cells to synthesize and secrete cytokines such as TNF and 
IFN-y. Since CD16 is a low affinity receptor, it can only bind to aggregate but not 
monomeric lgG (1). 
Antibody independent lysis is not as well understood as that for ADCC since no 
known definitive activating receptor for NK cells or ligand on target cells has been 
identified. There are several theories as to how this pathway may be activated. One 
is that direct cell-mediated cell lysis is triggered by an unidentified surface NK 
receptor to an unknown structure on a malignant or virally infected cell (1, 20). 
Another is that target cells lack expression of a normal protective molecule. The 
identification of the target molecule not being encoded in MHC class I or that lack of 
expression of MHC class I induces lysis. The latter theory is supported by the fact 
that virally infected cells and tumor cells have decreased MHC I expression. 
There is also the two-receptor model theory, which postulates regulation of NK 
lytic activity through inhibition of lysis. That is, the NK cell receives signals from two 
different receptors. One receptor binds to ligands on the target cell that are possibly 
carbohydrates, this is the signal to kill. This signal is prevented by a second receptor 
that binds to certain alleles of MHC class I. This negative signal overrides the 
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positive signal. Low MHC class I expression would result in a reduction of the 
negative signal so that the positive signal would be greater and result in killing (1, 
28, 44). 
Though no known activating receptor has been characterized for NK cells this 
has not been the case for inhibitory receptors found on NKcells. Inhibitory receptors 
have been found on macrophages, mast cells, and killer cells (13). There are 
inhibitory receptors that specifically bind to MHC class I molecules. On human NK 
cells there are two groups of inhibitory receptors. There are Type I transmembrane 
proteins with immunoglobulin domains and long cytoplasmic tails (76,84, or 95 
amino acids long) called killer inhibitory receptors (KIRs). There are.two families of 
KIRs, the p58 and p70 inhibitory receptors (18, 25). Three human NK KIRs have 
been characterized. GL 183 and EB6 (p58s) each have two lg domains and 
recognize HLA-C alleles at positions 77 and 80 on the a1 domain of the MHC class I 
molecule. NKB1 (p70) has three lg domains and recognizes the Bw4 epitope on 
HLA-B at positions 77-83 on the a1 domain of the MHC class I molecule (56). In 
addition there is also a homodimer of p70 called p140 that can recognize HLA-A 
alleles (13). Human KIR recognition of polymorphic determinates of HLA molecules 
has been found to be limited to the carboxy-terminal of the a1 domain of MHC class 
I (56). A second group of human inhibitory receptors are Type II transmembrane 
proteins with C type lectin extracellular domains. One type of this receptor, CD94/ 
NKG2, exists as a hetrodimer that also binds MHC class I (13, 25, 29). As CD94/ 
NKG2 has C-lectin domains, it may be able to bind to a common carbohydrate in 
different MHC class I alleles and would enable this receptor to have a broader 
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binding capacity allowing it to recognize remaining HLA-B and HLA-A alleles not 
recognized by the Type I Kl Rs. Both classes of inhibitory receptors have in common 
that they recognize and bind to MHC class I molecules but also contain two 
immunoreceptor tyrosine inhibitory motifs (ITIMs) separated by 26-28 amino acids in 
their long cytoplasmic tails (18, 37). 
It is hypothesized that NK inhibitory receptors prevent cell activation in certain 
conditions, times, or locations to protect sensitive areas. It is suggested that 
inhibitory receptors prevent harmful activity of NK cells while the cells mature and 
migrate where their presence is required (13). However, binding of KIRs does not 
lead to cell death or long-lived anergy. The identification of KIRs provides evidence 
to validate the two-receptor theory for activation. 
NK inhibitory receptors override activation signals to prevent lysis. When KIRs 
bind MHC class I ligand, downstream signaling events responsible for generating 
inositiol-1, 4,5-trisphosphate (IP3) and increasing intracellular calcium are shut down 
and there is a partial disruption of tyrosine phosphorylation (56). Upon engagement 
of KIR to MHC class I, tyrosine residues in the ITIMs are phosphorylated by a src 
family member (lck and lyn, but not fyn) (7, 14). This phosphorylation in turn recruits 
and activates the tyrosine phosphatase, SHP-1 (14, 15). SHP-1 appears to 
dephosphorylate an early substrate that is found in the activation pathway. A 
possible candidate for that substrate could be the adapter protein pp36 that 
associates with phospholipase C gamma (PLCy) or another adapter protein called 
Grb2. Grb2 and pp36 control PLCy enzymatic activity (55). For inhibition by KIRs, 
there must also be co-ligation with an activating receptor. This would suggest that 
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KIRs and activating receptors would need to be in close proximity to each other (13). 
There are a group of KIRs with short cytoplasmic tails (39 amino acids long) that 
have no ITIMs, and have a charged lysine in the transmembrane domain indicating 
they have the ability to associate with signal transducing molecules. These receptors 
are known as killer activating receptors (KARs) and have been proposed to be 
activating receptors for NK cells (18). 
Mechanism of Target Cell Lysis 
The process of target cell lysis by NK cells is the same whether initiated by 
ADCC or the Ab-independent pathway and is similar to that used by cytotoxic T 
lymphocytes. This process includes granule exocytosis and initiation of DNA 
fragmentation and apoptosis. As they contain large granules at all times in the 
cytoplasm, NK cells are always constitutively cytotoxic unlike T-cells which must be 
stimulated before granules appear. The cytotoxic process is initiated by the 
recognition of target through cell-to-cell contact. The contact occurs through CD16 
on an NK cell binding to lgG on a target cell or the binding of the unknown receptor 
and ligand for Ab-independent lysis. Once adherence takes place, a signal is sent to 
activate the lytic pathway. Degranulation of the NK cell occurs at the site of contact. 
NK granules contain perforin, granzymes (neutral serine proteases), proteoglycan, 
and cytotoxins. These substances deliver the "lethal hit" to the target cell. Perforin is 
a monomeric pore forming protein that requires the presence of calcium so it can 
bind to the target membrane and form a pore. After entering the target cell, 
granzymes bind to substrates that are involved with apoptosis or can be transported 
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to the nucleus where they can directly bind and activate death substrates. Cytokines 
such as TNF-a enter the target to further damage the target cell integrity. So unlike 
the "true" lysis seen with complement, NK cells activate an endogenous apoptotic 
pathway with granzymes leading to cell death. Proteoglycan (chondroitin sulphate A) 
protects the NK cell from self-destruction. After an NK cell delivers its "lethal" hit, it 
can be "recycled" to lyse other targets, become inactive, or undergo apoptosis (1, 
28, 31, 44, 47, 50). 
Natural Killer Cell Functions 
The two major roles of NK cells are immune surveillance against tumor cells and 
virally infected cells and the release of cytokines (specifically IFN-y) to activate 
macrophages and T lymphocytes (44). NK cells can inhibit proliferation of tumor 
cells and blood borne metastasizing tumor cells by their characteristic "natural" 
killing (42). Tumor cells have decreased MHC class I expression especially those 
tumors mediated by oncogenic viruses. While reduction of MHC class I 
compromises cytotoxic T lymphocyte activity, it seems to be one requirement for 
recognition and lysis by NK cells (1, 28). Tumor cells may also express specific 
surface proteins that NK cells recognize (1). NK cells can lyse tumor cells coated 
with antibody by ADCC and this killing is unaffected by the presence or absence of 
MHC class I. Chediak-Higashi syndrome and the animal model of this disease called 
beige mouse readily demonstrates the importance of NK cells in tumor immunity. In 
Chediak-Higashi patients, NK cell lytic activity is impaired due to an abnormality in 
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the granules that contain granzymes. Patients experience recurrent infections and 
an aggressive but nonmalignant infiltration of organs by lymphoid cells (1, 28). 
NK cells have other functions as they serve to control infections caused by 
viruses, parasites, fungi, and bacteria. NK cell produced cytokines are of more 
importance than NK lytic activity in controlling bacterial infections (53). Bacterial 
infections cause inflammatory signals that attract NK cells. NK cells can destroy 
extracelluar bacteria via ADCC by binding to opsonizing lgG bound to bacteria. 
Macrophages containing intracellular bacteria are stimulated to produce IL-12, which 
activates NK cells. In response to this activation, NK cells produce cytokines (IFN-y) 
to recruit other immune effectors involved with inflammatory responses (1, 22, 42). 
NK cells are not known to directly kill parasite-infected cells or parasites. NK cells do 
contribute to early opposition of parasitic infections by producing IFN-y to stimulate 
macrophage activity and influence a Th1 response to direct an adaptive immune 
response to parasitic infections (53). Viral infections directly activate the production 
of Type I IFN by the infected cells and down regulate MHC class I expression, all 
which serve to enhance and stimulate NK lytic function (1). 
NK cells function in immune regulation and the pathology of disease states. NK 
cells participate in immune regulation through the production of cytokines. Some of 
the immunoregulatory events that NK cell cytokines participate in are innate immune 
responses (chemokines, IL-1), regulation of lymphocyte activation, growth, and 
differentiation (IL-2, IL-4), immune directed inflammatory reactions (IFN-y, IL-12), 
and hematopoiesis (IL-3, GM-CSF). NK cells have roles in autoimmune disorders 
and graft vs. host disease (GVHD). When antibody binds to self-antigen as in 
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autoimmune diseases, CD16 on NK cells binds to lgG, which activates lysis by 
ADCC. GVHD occurs When grafted effector cells mount a rejection response to the 
host resulting in epithelial cell necrosis. NK cells cannot recognize allotype antigens 
but transplanted T helper cells do and are stimulated to produce IL-2. In response to 
IL-2, NK cells differentiate into LAKs that are able to lyse host epithelial cells (1). 
NK3.3 Cells 
Most studies of NK cells have been performed using partially purified cells from 
humans or animals since the method of harvesting NK cells by density gradient 
centrifugation with Ficoll-Hypaque does not yield a pure population. However, 
research on NK cell biology using partially purified NK cells was unable to rule out 
cytotoxicity due to other immune cells, eliminate possible cross-talk between other 
cell types, or solve the problem of collecting an adequate quantity of pure NK cells. 
A specific NK cell line was needed to eliminate these questions and link results 
specifically to NK cells. Dr. Jacki Kornbluth, St. Louis Univ., St. Louis, MO developed 
such a cell line. 
Dr. Kornbluth developed the NK3.3 line, a human cell line, from a primary mixed 
lymphocyte culture (MLC). This was accomplished by harvesting peripheral blood 
leukocytes (PBL) by density gradient centrifugation from heparinized blood provided 
by two healthy donors. The responder PBLs were incubated with an equal number of 
irradiated stimulator PBLs for six days, 37° C, and 5% CO2 (6 day MLC). From the 
primary culture, 1 - 2.5 x 105 cells were plated in 1 ml of 0.45% agarose containing 
RPMl-1640 complete media, 20% human serum, and 30% IL-2 conditioned media. 
14 
This mixture was plated in a 24 well plate at 1 ml per well and incubated for another 
6 days at 37° C. Individual colonies were removed from the agarose and expanded 
in microtitier plate wells with liquid media containing RPMl-1640 complete media, 
15% human serum, and 20% IL-2 conditioned media. Colony 3 after being 
maintained in IL-2 conditioned media for one month was split into 8 separate wells. 
The NK3.3 cell line is a subculture from one of the individual colonies (27). 
NK3.3 cells are morphologically and cytochemically similar to LGLs. NK3.3 has a 
high cytoplasm to nucleus ratio, azurophilic granules in the cytoplasm, and is 
capable of strong direct cell contact lysis but has weak lysis by ADCC. The NK3.3 
target specificity was established using cold target inhibition assays. The NK3.3 cells 
can lyse the following NK susceptible lysis cell lines in order of strongest to weakest 
cytotoxicity: K562, MOL T-4, BUG, HSB-2, GEM, and DAUDI. NK3.3 is an IL-2 
dependent cell line (27). Phenotypically NK 3.3 is CO2+ (E-rosette receptor), CD3-
(accessory T-cell receptor), CD4/8- (T-helper and T-cytotoxic markers), CD16+ 
(FcyRIII receptor), CD38+ (ADP-ribosyl cyclase), CD45+ (tyrosine phosphatase), 
CD56+ (adhesion molecule), HLA-DR+, -DP+, -DQ+, and no TCR (17). 
The NK3.3 cells have been used to observe what factors affect cytotoxicity. 
As NK3.3 cells are constitutively active due to IL-2 dependence, they were used to 
show that IL-2 activated NK cells natural cytotoxicity is reversibly inhibited by 
extracellular nucleotides with increasing negative charge in a manner similar to non-
stimulated NK cells. However, when using the adenine nucleotide analog, 5'-
p(fluorosulfonyl)benzoyladenosine (5' FSBA), cytotoxicity was found to be 
irreversibly inhibited. This information can be used to discover the role that 
15 
nucleotide-binding proteins have on extracellular regulation of cytotoxicity of NK cells 
(19). The natural killer tumor recognition (NK-TR) protein was found to be necessary 
in the activation of direct cell contact lysis by NK3.3 ceHs (40). Glucocorticoid 
suppression of NK cytotoxicity was investigated using NK3.3 cells. Through the use 
of micromolar concentrations (1-10 µM) of cortisol with NK3.3 cells, the following 
molecular mechanisms contributing to suppression were observed: granzyme A 
synthesis suppressed, down regulation of adhesion molecules, reduced ability to 
form conjugates with K562 cells, and lytic activity abolished (69). 
The NK3.3 cells have been used in various research studies to provide 
explanations for biochemical and molecular events that mediate signaling events 
related to NK cell functions. Cone, et al., (17), used NK3.3 cells to demonstrate that 
the src protein tyrosine kinase p561ck was linked to CD16 and was a signal 
transducer for ADCC. The NK3.3 cells have been used to show that NK cells 
respond to IL-2 and IL-12 to produce IFN-y and granulocyte-macrophage colony-
stimulating factor (GM-CSF) by using separate and distinct pathways to induce IFN-y 
and GM-CSF gene expression (64). An association between the phosphatase CD45 
and p561ck kinase and its effects on IFN-y production has been demonstrated with 
the NK3.3 cells (61). Stimulation of NK3.3 cells with IL-12 and IL-2 was shown to 
result in phosphorylation of distinct but related Janus (JAK) family tyrosine kinases. 
IL-12 stimulated phosphorylation of Tyk2 and JAK2 whereas JAK1 and JAK3 were 
phosphorylated in response to IL-2. This research demonstrated that even though 
these two cytokines work together synergistically both use separate signaling 
pathways (4). The NK3.3 cells were used to establish a signaling pathway linking 
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CO2 mediated granular exocytosis with p72syk kinase, the adapter protein She, and 
phosphatidylinositol 3-kinase (Pl3K) activity (54). NK3.3 has been used to analyze 
the molecular events that occur in response to stimulation with IL-2, IL-12, and IFN-y 
on JAK-STAT (signal transducer and activators of transcription) signaling pathways 
(65). 
NK3.3 cells were used to see if Pl3-kinase (p85a) physically associated with 
ITIMS (immunoreceptor tyrosine-based inhibitory motif) found in KIR (killer cell 
inhibitory receptors) cytoplasmic tails in NK cells. Cross-linking of KIRS on NK3.3 
cells by GL 183 was performed to determine whether this would lead to recruitment 
of p85a. KIRs were immunoprecipated from exponentially growing NK3.3 cells with 
GL 183 (anti-KIR, lgG) and blotting with p85a antibody detected p85's presence. It 
was found that cross-linking by GL 183 did induce association between KIR and 
p85a (34). 
In parallel, KIR cross-linking by GL 183 was examined for increased lipid kinase 
activity of Pl3-K. In these assays, p85a was immunoprecipated from NK3.3 cells that 
were cross-linked with GL 183 and p85a was assayed for its ability to transfer 32 P to 
Pl4-phosphate. It was observed that Pl3-K activity paralleled the recruitment of p85a 
to KIR cytoplasmic tails (34). 
Pl3-K is upstream of other signaling intermediates. It was observed that another 
consequence of KIR cross-linking by GL 183 was the activation of AKT by Pl3-K. 
AKT is a serine/threonine kinase credited with anti-apoptotic activity. This result 
suggested that Kl Rs could also convey positive signals for growth and survival. 
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Activation of AKT would protect NK cells from apoptosis. This means that not only 
could KIR participate in inhibitory signaling but also positive signaling (34). 
NK3.3 cells have been used to examine cell cycle progression in NK cells. 
Yamauchi and Bloom (63) used NK3.3 cells to define the intracellular events that 
could be induced by the absence of a reducing environment. It had been previously 
found that IL-2 stimulated functions were subjected to downstream redox regulation. 
NK3.3 cells cultured in a thiol-deficient, IL-2 containing media failed to proliferate. 
This was due to NK3.3 cells being arrested in the G1 phase and unable to move on 
to the DNA synthesis phase of the cell cycle. Thus, for IL-2 stimulated NK3.3 cells to 
proliferate and function they require a reducing environment for normal cell cycle 
progression. 
Overall, NK3.3 cells have been used extensively in defining NK cell activation, 
regulation, signal transduction mechanisms, and should prove useful in the 
evaluation of new biological response modifiers. 
Biological Response Modifiers 
Biological response modifiers are substances made from living organisms that 
can produce an action or change a condition. Cytokines are one example of a 
biological response modifier. Cytokines are low molecular weight soluble proteins 
made and secreted by cells that can influence the function of other cells expressing 
specific surface receptors. Cytokine receptor binding triggers signal transduction 
pathways to a.lter gene expression (28, 44). Lymphocytes are an important source of 
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cytokines as well as macrophages. Cytokines have functions in the immune system 
but also have roles in other systems such as developmental biology (23). The term 
cytokine is used for a large group of diverse molecules. However, cytokines can be 
categorized into four principal groups by their actions. The first group are those 
cytokines that mediate innate immunity and include the type I interferons (IFNs) that 
are the first line of defense for viral infections as well the cytokines which mediate 
inflammatory reactions (TNF, IL-1, IL-6, chemokines). The second group of 
cytokines are those produced by antigen stimulated T helper cells and act to 
regulate the growth, activation, and differentiation of T and B cells (IL-2, IL-4, TGFp). 
The third group are the cytokines that are produced by activated T helper and T 
cytotoxic cells and activate inflammatory leukocytes (INF-y, lymphotoxin, IL-10, IL-5, 
and IL-12). The fourth group of cytokines are called colony-stimulating factors. Bone 
marrow stromal cells and T cells produce these cytokines in order to stimulate the 
growth and differentiation of bone marrow progenitor cells (1). 
Cytokines are able mediate a broad range of activities in the immune system. NK 
cells are regulated by specific cytokines and also secrete specific cytokines in 
response to a stimulus. 
The most potent activators of NK cells are IL-2, IL-12, and INF-y. IL-12 was 
formerly know as NK stimulating factor and is a protective cytokine in infections 
involving intracellular pathogens. IL-12 activates, induces proliferation, and 
enhances the secretion of IFN-y and cytotoxicity of NK cells (23, 47). IL-12 works 
best in synergy with IL-2 to activate NK cells (44). IL-2 was previously known as T 
cell growth factor (47). The major function of IL-2 is to induce immune responses. IL-
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2 is made primarily by T helper cells after stimulation by MHC class II and antigen 
stimulation. IL-2's effect on NK cells is to increase lytic activity, induce clonal 
expansion, and generate differentiation to LAKs (23, 44). Interferon gamma (IFN-y) 
is best known as a major activating factor for macrophages as it increases their 
metabolism, phagocytic and killing activities, especially those involving intracellular 
pathogens. IFN-y also increases MHC class I expression and induces MHC class II 
expression. IFN-y is able to induce differentiation of Beel.I$ and NK cells and affect T 
cell development. It can increase NK cell adherence to target cells and activate and 
increase the rate of target lysis (23, 44). 
To a lesser degree the following cytokines are also known to activate NK cells: 
IL-1, IL-15, and Type I interferons (a and P) (28). IL-15 has similar effects to IL-2 as 
it increases proliferation and effector function of NK ceUs. IL-1 is a T cell activator 
and enhances NK cell activity (23, 28). Type I interferons (a and p) are secreted by 
virally infected cells and stimulate NK cells. This activity of NK cells by IFN-a and 
IFN-P is the first line of defense to viral and some bacterial infections until T cytotoxic 
cells differentiate into cytotoxic T lymphocytes (28). 
Recent studies with chemokines (chemotactic cytokines) have shown that they 
too can increase cytotoxicity and direct the migration of NK cells to sites of 
inflammation and tumor cells (32). Chemokines are low molecular weight heparin 
binding polypeptides that are released at inflammatory sites and initiate the 
migration of immune cells. Chemokines are divided into families by the location of 
cysteine residues in the NH2 terminus: CXC (a), CC (P), C (y), and CX3 C (8). 
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Chemokines also mediate expression and/or adhesiveness of leukocyte integrins 
and are specific for cell types. Chemokine binding to its receptor triggers an 
activating signal that is mediated by heterotrimeric G-proteins that are associated 
with the receptor. The signal induced by chemokine binding causes a conformational 
change in the integrin molecules on the cell membrane. This increases the affinity of 
intergins for adhesion molecules. Cells will migrate in the direction of high 
concentrations of chemokines (28, 47). 
NK cells do not normally recirculate between blood and lymphoid tissues but they 
can after the administration of biological response modifiers such as chemokines. 
LAK cells do not migrate towards tumor sites (32). Chemokines induce chemotaxis 
of NK cells and mobilization of their intracellular calcium, which is a common second 
messenger in signaling events. The CC (P) chemokines in particular induce granule 
exocytosis of NK cells therefore activating and enhancing their cytotoxicity. 
Research with chemokines and NK cells suggests that chemokine activated NK cells 
are bettered suited for tumor therapy than IL-2 activated LAK cells. NK cells have 
better migratory behavior (extravasate into tissues) than LAK cells which do not 
respond to chemokines and do not migrate to tumor sites. Moreover, to maintain 
LAK cells in vivo, a continuous infusion of IL-2 is required which can be toxic in high 
doses; this is not the case with chemokines. Chemokines attract and activate NK 
cells at sites of viral infection to lyse virally infected cells. Chemokines also have the 
ability to inhibit repl.ication of HIV-1 infected cells by binding to chemokine co-
receptors. Taken together these actions suggest that chemokines can be used as 
tools to study signal transduction pathways in NK cells (32). 
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NK cells must be activated to synthesize and secrete cytokines. The dominant 
cytokine that NK cells are known to produce is IFN-y. IFN-y is also called immune or 
type II interferon and is a cytokine that regulates immune-mediated inflammation. 
Like type I interferons, IFN-y is antiviral and antiproliferative. However, IFN-y binds to 
a different cell surface receptor and also has immunoregulatory functions affecting 
primarily macrophage activation ( 1). 
Activated NK cells also produce tumor necrosis factor-a (TNF-a) and 
granulocyte-macrophage colony stimulating factor (GM-CSF) (55). TNF-a also 
referred to as cachetin, is a prominent inflammatory cytokine with a wide range of 
activities. Early studies of this cytokine showed that it could kill tumor cells in tissue. 
TNF-a is an endogenous pyrogen, induces leukocytosis, enhances endothelial 
adhesiveness, and enhances the production of other cytokines. GM-CSF is a 
cytokine that is important for the development of myefoid lineage-specific bone 
marrow stem cells. GM-CSF sends strong signals to induce TH 1 differentiation and 
response (23). 
Activated NK cells secrete the following interleukins: IL-1, IL-2, IL-3, IL-4, and 
IL-12 (28, 42, 47). The primary function of IL-1 is that of a mediator cytokine of a 
host inflammatory response in innate immunity (1). IL-1 stimulates T and B cells, 
travels to the brain to induce fever and augment corticosteroid release, and induces 
the production of acute phase proteins in the liver. An example of an inflammatory 
response that IL-1 participates in is the production of prostaglandins and degradative 
enzymes (collagenase) that are involved in cartilage and bone destruction (47). 
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With the production of IL-2 and IL-12, one should note that cytokines, like 
hormones, demonstrate autocrine action, meaning that the cell that produces the 
cytokine can also be the target of the cytokine. These two cytokines when working 
together are potent effectors of NK cell and CTL cytotoxic activity. IL-12 stimulates 
naive T cells to TH 1 response while IL-2 contributes to the growth and 
differentiation of 8 cells (1, 47). 
IL-3 is also known as the multilineage colony-stimulating factor (multi-CSF) (1). 
This interleukin works as a haemopoietic growth factor by stimulating the 
proliferation and differentiation of bone marrow pluripotential stem cells and lineage 
committed precursors (23). IL-4 is a B cell growth factor cytokine that leads to 
activation and differentiation of B cells. IL-4 drives the immune response towards 
humoral and antibody production particularly lgG1 and lgE. IL-4 is a growth factor for 
mast cells and works in synergy with IL-3 to stimulate mast cell proliferation. IL-4 
can also up regulate the expression of specific adhesion molecules (example 
VCAM-1 ). IL-4 is a growth and activation factor of T cells directing them towards a 
TH 2 response and an inhibition of IL-1 and TNF (1, 23, 47). 
NK cells can be stimulated by and produce cytokines to biologically modify the 
response of the immune system. However, biological response modifiers are 
perhaps not the only substances to effect on NK cell activity. This research will 
examine genistein, a phytochemical, which can modify the cytolytic response of NK 
cells against target cells. 
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Genistein 
Phytochemicals are plant derived bioactive non-nutrients (48). One group within 
the phytochemicals is the phytoestrogens that have nonsteroidal structure that can 
act as estrogen receptor agonist or antagonists (48). Two main classes of 
phytoestrogens are lignans and isoflavones (49). The chemical structure of 
isoflavones is similar to mammalian estrogen due to the presence of a phenolic ring 
(49). This phenolic ring is a condition required for compounds that bind the estrogen 
receptor (ER) (30). 
lsoflavones are found in high concentrations in soybeans and soy-derived 
proteins. The major isoflavones in soybeans are the isoflavone glycoside conjugates 
genistin and daidzin, and the isoflavone aglycones genistein and daidzein (58). 
lsoflavones have been discovered to have a broad range of hormonal and 
nonhormonal activities that aid in the prevention of hormonal-dependent diseases 
such as cancer (49). The isoflavone thought to be responsible for these activities is 
genistein. Genistein is believed to be responsible for anti-estrogenic and anti-
carcinogenic activity in hormone dependent diseases (59, 67). However, for the 
most part, little is known about the mechanisms by which genistein performs these 
activities. 
Genistein has been shown to be a specific inhibitor of tyrosine kinases. Akiyama, 
et al, observed genistein to inhibit epidermal growth factor (EGF) stimulated tyrosine 
phosphorylation of A431 cells. Further, it was seen that genistein competed with 
ATP and inhibition by genistein binding to enzyme-substrate complexes. This finding 
may explain why those eel.ls lacking estrogen receptor are affected by genistein (2). 
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Genistein is believed to stimulate proliferation through estrogen receptor 
mediated pathways while its anti-proliferative actions are thought to be due to 
inhibition of tyrosine kinases (59). Two research studies have examined the anti-
estrogenic effects of genistein on MCF-7 cells, a human breast cancer cell line that 
is positive for ER (59, 67). Both studies examined genistein's effects on ER binding, 
pS2 mRNA expression, pS2 protein, and cell proliferation. Wang, et al, (59) 
determined that genistein's effects were biphasic. At low doses, 1 o-8 to 10-5 M, 
genistein stimulated proliferation of MCF-7 but not an ER negative cell line (MDA-
MB-231 cells). Genistein also stimulated pS2 mRNA expression and competed with 
estradiol to bind to ER in the MCF-7 cell line. At high doses, 2.5 x 10-5 to 10-4 M, 
genistein failed to stimulate MCF-7 pS2 mRNA expression and inhibited the 
proliferation of MCF-7 and the ER negative cell line. Wang, et al, (59), concluded 
that dietary genistein effects on hormone dependent diseases were ER dependent. 
This was because circulating genistein levels (62) would never reach levels seen 
with inhibition. 
Zava and Duwe, (67), repeated the same procedures to examine geinstein's 
estrogenic properties and antiproliferative activities. In addition, several other 
structurally similar iso- and bioflavonoids were used to compare with genistein's 
actions on MCF-7 cells. They concluded that genistein mediated ER dependent and 
independent activity over physiological concentration ranges (10 nM -20µM) (67). 
The biphasic responses related to concentration were also noted. These studies 
suggested that genistein acts as an estrogen agonist at physiologic concentrations. 
However, at increased genistein concentrations, when proliferation was inhibited, the 
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pS2 protein was present suggesting an ER-independent cellular mechanism(s) may 
inhibit the ER-dependent proliferation (67). 
Signal Transduction during NK Cell Activation 
In cell biology, signal transduction is the process by which a cell converts an 
extracellular signal to produce intracellular signals to cause physiological responses. 
These responses can coordinate differentiation, development, cell maintenance, and 
metabolism (3). Signal transduction by ligand binding and/or biological response 
modifiers in NK cells results in proliferation, cytokine secretion, differentiation into 
LAK cells, and lytic activity. 
Let's focus on those signaling events that mediate the cytotoxic function of NK 
cells by ADCC and natural cytotoxicity. Early and necessary events for these 
separate modes of killing include protein tyrosine kinase activation, release of 
phosphoinositides, and increase in free intracellular calcium (20, 42, 51). Cytolytic 
function mediated by ADCC is initiated by signaling through Fey being bound by the 
Fe portion of antibodies bound to antigen. This receptor consists of a ligand-binding 
a subunit (CD 16) with noncovalently bound hetro- or homodimers of s (a 
component of TCR) and y (a component of FcyRI) subunits. This multi-subunit 
receptor itself does not have intrinsic kinase activity but the s and y subunits contain 
immunoreceptor tyrosine-based activation motifs (ITAMs) that aid in the generation 
of intracellular second messengers (9, 31). Upon binding of FcR, the ITAMs are 
phosphorylated by an intracellular PTK that enables the receptor to become coupled 
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with downstream signaling events. Two nonreceptor tyrosine kinase families, src (in 
NK cells Lek, Fyn, Yes, and Lyn) and syk (in NK cells Syk and ZAP-70), are thought 
to be responsible for this activity (9, 11, 31). In particular, the src-family kinase Lek 
has been linked to this phosphorylation activity since it has been found to physically 
associate with FcyRIII complex (17). Phosphorylation of ITAMs by Lek enables syk 
family kinases (ZAP-70 and Syk) to bind to them (11, 31). However, FcR complex 
signaling can occur in the absence of Lek, Fyn (another src-family kinase) also 
thought to couple with the receptor, and ZAP-70 (38, 57, 60). It has also been 
demonstrated that Syk activation (Lek independent) alone is sufficient to generate a 
cytotoxic response while ZAP-70 (Lek dependent) requires co-stimulation by a src 
family kinase (26). These findings prompted research looking into Syk kinase as the 
signaling element used to tyrosine phosphorylate ITAMs and initiate downstream 
signaling events. Through the use of pharmacological inhibition of Syk kinase activity 
(piceatannol, ~ 6 µg/ml), expression of dominant-negative kinase inactive Syk, and 
tumor cells transfected with MHC class I, it was determined that Syk kinase was an 
early and central signaling protein in ADCC and natural cytotoxicity (10). 
Once the FcR complex gathers its activated kinases, it can activate a number of 
downstream signaling molecules. One of these substrates is phospholipase C-y 
(PLC-y) that is an enzyme that hydrolyzes phosphoinositides. The products from that 
reaction, inositol trisphosphate (IP3) and sn-1, 2-diacylglycerol (DAG), mediate the 
. increase in free intracellular calcium and the activation of protein kinase C (PKC) 
(9). The increased concentration of free intracellular calcium is required for the 
release of granules in the delivery of the "lethal" hit (31 ). 
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Another downstream effector of FcR signaling is phosphatidylinositol 3-kinase 
(Pl-3K). It was once thought that cytotoxic activities initiated through FcR ligation 
were PKC dependent since PKG-activating phorbol esters and calcium ionophores 
could induce NK cytotoxicity. However, it was shown that ADCC still occurred even 
in the presence of PKC inhibitors. It was found that natural lysis was PKC dependent 
while FcR lysis was Pl-3K dependent (8). 
Not only does the Fe-induced tyrosine kinase cascade activate downstream 
enzymes but it also activates small molecular weight GTP-binding proteins (G 
proteins). In the case of Ras, a G protein involved with mitogenic signaling 
pathways, it becomes activated by adapter proteins that have been phosphorylated 
by proximal PTKs induced by ligation of FcR. The adapter proteins p36 and She are 
tyrosine phosphorylated by these PTKs and then binds to another adapter protein, 
Grb2, which binds to Sos, the guanine nucleotide exchange factor for Ras. Sos 
stimulates inactive Ras to give bound GDP for GTP to become activated (9, 11 ). 
Ras activation is believed to regulate transcriptional events that mediate NK cell 
effector functions following receptor ligation (31). The guanine nucleotide exchange 
factor (GEF) Vav is tyrosine phosphorylated after FcR ligation after which it activates 
its downstream effector Rac1 (a small G protein). It has been shown that over 
expression of Vav enhances NK cell cytotoxicity and that a mutation that prevents 
Vav from mediating GTP for GDP on Rac1 will abolish this enhancement. Dominant-
negative Rac1 has also been shown to inhibit NK cell mediated lysis. This all 
suggests that Rac1 is a downstream effector involved with regulation of cytotoxicity. 
This event is also observed with natural killing of target cells (6). 
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Signal transduction studies dealing with natural cytotoxicity have been hindered 
by a clear molecular characterization of a triggering receptor. Natural cytotoxicity like 
ADCC utilizes protein tyrosine kinase activation, PLC-y release of phosphoinositides, 
and an increase in free intracellular calcium (20, 41, 51 ). Because natural 
cytotoxicity shares these early and requisite events with ADCC there was 
speculation that a receptor with ITAM subunits could be involved. Research has 
shown that if this is the case it would not be due to the sandy since NK cells lacking 
these units can perform natural cytotoxicity (52). And like ADCC, Lek, Fyn, or ZAP-
70 are not required for natural cytotoxicity (38, 57, 60). However, a central role for 
Syk tyrosine kinase was discovered in natural cytotoxicity (10). Natural cytotoxicity 
was found to be PKC dependent, Pl-3K independent (8). Vav and its effector target 
Rac1 were found to have a role in regulating natural cytotoxicity (6). There is 
evidence that natural cytotoxicity can occur in the absence of PLC-dependent 
calcium signaling (43, 66). 
Summary 
Innate immunity is the first line of defense of the immune system. Natural killer 
cells play a role in innate immunity as effector cells. Tyrosine phosphorylation has 
been implicated as a signal for lytic activity of NK cells (20). In vitro studies with 
isoflavones, genistein and daidzein, have been shown to enhance NK lytic activity of 
peripheral blood leukocytes. This study was designed to ask if low concentrations of 
genistein had a direct effect on natural killer cell lytic activity and if this effect was 
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related to tyrosine phosphorylation. A pure NK cell line, NK3.3, a chromium release 
assay, and flow cytometry were used to study the direct effects of geniste,in on NK 
cells. 
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MATERIALS AND METHODS 
Chemicals 
Recombinant human Interleukin 2 (IL-2) (1-2644), Staurosporine A (S-4400), 
Saponin (S-79O0), Sodium Orthovanadate (S-6508), Catalase (C-40), 3,3' -
Diaminobenzidine (D-8001) were obtained from Sigma, St. Louis, MO. 
Formaldehyde, 16%, Ultra Pure, was obtained from Polysciences Inc., Warrington, 
PA. Sterile sodium chromate (51 Cr) obtained from NEN Dupont, Boston, MA. 
Genistein was synthesized in the laboratory of Dr. Patricia Murphy, Iowa State 
University, according to Chang et al (16). Genistein was analysed on a Beckman 
System Gold chromatography with an autosampler Model 507 (68). 
Antibodies 
Monoclonal anti-phosphotyrosine FITC- conjugate (F-3145) and mouse lgG1K 
(MOPC-21) FITC - conjugate (F-6397), monoclonal anti-phosphotyrosine (P-3300) 
and anti mouse lgG (Fab specific) peroxidase conjugate (A-2304) were obtained 
from Sigma, St. Louis, MO. 
Isolation of NK Cells from Peripheral Blood 
Blood was diluted 1 :2 with washing solution. Washing solution was Hanks' 
Balanced Salt Solution (HBSS) and 25 mM Hepes (Gibco BRL, Grand Island, NY). 
Eight mis of diluted blood was slowly layered over 3 mis of Ficoll-Hypaque 
(Pharmacia Biotech, Pisctaway, N.J.) in a 15 ml centrifuge tube. Blood samples 
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were centrifuged at 1500 rpm for 20 minutes at 20° C. After centrifugation, plasma 
was pipetted and discarded. The buffy coat at the interface was collected by gently 
circling the centrifuge tube with a pipet. The buffy coat was then placed into 8 mis of 
washing solution and centrifuged at 1500 rpm for 5 minutes at 20° C. Media was 
removed with just enough to cover resultant pellet of white blood cells. The pellet 
was resuspended by knocking tube on a hard surface. Eight mis of washing solution 
was added and the tube was centrifuged at 1500 rpm for 5 minutes at 20° C. This 
step was repeated on more time but with complete media. After removing media and 
resuspending the pellet, 1.5 mis of complete media was added to the tube. Cell 
concentration of the sample was measured and test samples made from that 
concentration. 
Cell Culture 
NK3.3, a human cell line cloned from a primary mixed lymphocyte culture and 
phenotypically distinct from characterized PBL T-cell populations (27), were kindly 
provided by Dr. Jacki Kornbluth, St. Louis Univers.ity, St. Louis, MO. NK3.3 cells 
were maintained in RPMl-1640, 2 mM L-glutamine, 25 mM Hepes, 50 ug/ml 
gentamicin (Gibco BRL, Grand Island, NY), 15% FBS (JRH, Biosciences, Lenexa, 
KS) and 15% Lymphocult-T (Biotest Diagnostics Corp, Denville, NJ) at 37° C, 6% 
CO2. Cell culture density was maintained at 2.5 - 3 X 105 cells/ml. 
K562 (ATCC, Rockville, MD), a myelogenous leukemia cell line, sensitive to NK 
cell lysis were maintained in RPMl-1640, 2 mM L-glutamine, 10 mM Hepes, 50 ug/ml 
gentamicin (Gibco BRL, Grand Island, NY), and 10% FBS (JRH, Biosciences, 
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Lenexa, KS) at 37° C, 5% CO2 . Cell culture density was maintained at 3-9 X 105 
cells/ml. 
Generation of Activated and Rested NK3.3 Cells 
As NK3.3 cell activity varied as a result of IL-2 presence, cells were synchronized 
by activation with Lymphocult-T (the IL-2 source). NK3.3 cells were activated by 
resuspending cells in fresh media containing Lymphocult-T (15%) for 24 hours to 
bring all cells up to the same level of activity. Cells could be used after 18-20 hours 
for studies of "activated" NK3.3 cells. NK3.3 cells were separated into activated and 
rested media conditions after 24 hours stimulation with Lymphocult-T (15%). Cells 
defined as "activated" were resuspended again in fresh media containing 
Lymphocult-T for 18-20 hours prior to use in chromium release assays and flow 
cytometry methods. Cells defined as "rested" were resuspended in fresh media 
without Lymphocult-T for 18-20 hours prior to use in chromium release assays and 
flow cytometry methods. 
NK3.3 Cell Stimulation and Inhibition 
Human recombinant IL-2 was used in flow cytometry and chromium release 
assay at concentrations of 2.5, 5, 10, and 15 International Units (IU). Rested NK3.3 
cells were incubated with IL-2 for 30 minutes at 37° C, 5% CO2 for the chromium 
release assay and for 10 or 30 minutes at 37° C, 5% CO2 for flow cytometry. IL-2 
was used to restimulate NK 3.3 cells to respond to a natural ligand. 
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The following reagents were used in flow cytometry to manipulate intracellular 
tyrosine phosphorylation of NK3.3 cells. Sodium pervanadate (Na3 V04), a 
phosphatase inhibitor, was stored as-a 50 mM vanadate solution in dH2 0. Prior to 
use, a vanadate solution of 5 mM was reacted with 1 mM H2 0 2 (equal portions) for 
15 minutes at RT. Catalase (200 µg/ml) was added for 15 minutes at RT to remove 
residual H2 0 2. The final concentration of pervanadate is denoted by final vanadate 
concentration. Staurosporine A was used as a tyrosine kinase inhibitor. A working 
concentration of 2 µM was used. NK3.3 cells were incubated with sodium 
pervanadate or staurosporine A for 10 minutes prior to staining for flow cytometry. 
Genistein dilutions were made from a 10 mg/ml DMSO stock solution. Diluent 
used to make dilutions was a 2.5% DMSO/complete media mixture. Genistein was 
diluted and incubated with NK3.3 cells at final concentrations of 0, .1, .25, .5, 1, 2.5, 
5, and 10 µM. Genistein dilutions used for flow cytometry were diluted with 
phosphate buffered saline (PBS)/2.5% DMSO. NK 3.3 cells were incubated with 
genistein for 30 minutes at 37° C, 5% CO2 for the chromium release assay. NK3.3 
cells used in flow cytometry were incubated with genistein for 10 and 30 minutes at 
37° C, 5% CO2. The final concentration of DMSO was .025% and maintained 
constant across all dilutions for these assays. NK3.3 cells that were either incubated 
for 18-20 hours in fresh media with (activated) and without (rested) Lymphocult-T 
prior to use in cytotoxicity assays or fluorescent staining of intracellular 
phosphotyrosine residues. 
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Chromium .Release Assay 
The lytic ability of the NK 3.3 cells was measured by the amount of radioactivity 
released by K562 cells labeled with 51 Cr. Activated and rested NK3.3 ceHs were 
washed once and suspended in complete media at 2.85 X 106 cells/ml. K562 cells 
were incubated with 200 µCi of 51 Cr at 37° C, 5% CO2 for 70 minutes. K562 cells 
were washed three times and suspended in complete media at 1. 7 X 105 cells/ml. 
Effectors (NK3.3 cells) and target (K562) cells were plated in a E:T ratio of 50:1 in a 
final volume of 250 µI per well in a 96 well microtiter plate (Costar, Corning, NY). 
Spontaneous and total release controls were performed for each assay to establish 
natural release of 51 Cr (spontaneous) and maximum (total) release by complete lysis 
of K562 cells. All samples and controls were assayed in triplicate. The assay 
samples and controls were incubated at 37° C, 5% CO2 for 3 hours. After incubation, 
150 µI of 10% TCA was added to total control wells and the plate centrifuged at 500 
rpm for 5 minutes (Jouan, Inc., CR3-21). One hundred µI of supernatant was 
removed from each well and placed in a one ml macrotubule (Phenix Research 
Products). Radioactivity was measured by a Gamma Trac 1191, (Tracor Analytic, 
Elk Grove Village, IL). The lytic activity of the NK3.3 cells was calculated using the 
formula: 
cpm experimental value - cpm spontaneous 
cpm total - cpm spontaneous 
Spontaneous release was consistently < 10%. 
X 100 = % cytotoxicity 
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lmmunofluorescence Staining 
A method for labeling intracellular phosphotyrosine residues was adapted from 
the methods of Farahi Far et al., (21) and Hubert et al., (24) for flow cytometry with 
NK3.3 cells. Activated and rested NK3.3 cells were washed once and suspended in 
PBS at a concentration of 5 x 106 cells/ml. One hundred µI of cells were placed in an 
eppendorf tube with an equal volume of the following reagents: pervanadate, 
staurosporine A, IL-2, or genistein. Incubation time was for either 10 or 30 minutes. 
Treatment was stopped by washing NK3.3 cells with 600 µI PBS/Na3 N3 /BSA (wash 
buffer) for 1 minute at 2000g in a microfuge. Samples were fixed with 200 µI of 4% 
FMA for 10 minutes at 4° C. Samples were then washed once with 200 µI of 0.1 % 
permabilization solution (wash buffer containing saponin). NK3.3 cells were 
suspended in 100 µI of permabilization solution and 7µ1 a 1 :2 dilution of FITC-
conjugated anti-phosphotyrosine antibody and incubated for 30 minutes on ice in the 
dark. Samples were washed twice with permabilization solution (200 µI) and once 
with wash buffer (200 µI). Samples resuspended in 1 ml of wash buffer prior to 
analysis by flow cytometry. Mean fluorescence was used as a parameter rather than 
% population to give better specificity for the results. Mean fluorescence is the 
average fluorescence of all cells in the sample. 
Fl.ow Cytometry Analysis 
Analysis was performed on a XL-MCL (Coulter Corp., Miami, FL). Green 
fluorescence from FITC was collected through a 525 nm bandpass filter. Samples 
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were gated on forward scatter and side scatter (linear). Ten thousand gated events 
in a bit map were analyzed for each sample. Data was stored in a listmode file for 
reanalysis using Elite Software (Coulter Corp). 
Statistical Analysis 
A computerized program for analysis of variance (ANOVA, Statistix, NH 
Analytical Software) was used to assess differences between baseline and 
experimental values. ANOVA was used to examine the effects of 11 concentrations 
of genistein on activated NK3.3 cell lysis while a 2 X 11 ANOVA was used to 
examine the effects of genistein (11 concentrations) and IL-2 (-/+) on rested NK3.3 
lysis. A 2 X 11 ANOVA was used to examine the effects of genistein (11 
concentrations) and vanadate (-/+) on activated and rested NK3.3 cells intracellular 
tyrosine phosphorylation. The level of significance for the F test was set at p < .05. 
Chromium Release Assays 
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RESULTS 
Studies with "NK-rich" populations 
Chromium release assays were performed with NK cells harvested from 
peripheral blood leukocytes stimulated with genistein and daidzein. Figure 1 shows 
the average percent cytotoxicity of 8 chromium release assays with baseline set at 
100% to standardize results. Baseline cytotoxicity for "NK-rich" samples varied 
between 13 to 58.8%. Lytic activity was 40% higher than that observed at baseline 
cytotoxicity. Lytic activity was significantly enhanced at concentrations 0.1 µM to 1.0 
µM of daidzein and genistein (p< .001). Lytic activity was significantly suppressed at 
concentrations 2.5 µM to 10.0 µM. The amount of suppression due to these 
concentrations was found to be significantly greater with genistein (p < .003). We 
hypothesized that lytic enhancement was linked to tyrosine phosphorylation. As 
genistein was known to affect PTK's, we choose to study genistein in subsequent 
experiments. To see if enhancement of lytic activity was due to specific effects on 
NK cells, research with genistein was conducted on a NK cell line, NK3.3 cells (27). 
Activated NK3.3 cells used to establish chromium release assay parameters 
Activity of tumor killing by NK cells can be mea$ured using a chromium release 
assay. However, the initial rate of lysis for NK3.3 is more rapid than that of freshly 
harvested peripheral NK cells and the 4.5-hour incubation regularly used for the 
chromium release assay did not yield the anticipated lytic activity. A kinetic study 
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flgure 1. lsoflavone enhancement of "NK-rich" cells. Genistein and daidzein enhanced lytic activity of NK cells 
harvested from peripheral blood. This enhancement was observed at .1 µM to .5 µM genistein with a 40% increase of 
lytic activity over baseline. The graph represents the average of 8 chromium release assays. 
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(33) with NK3.3 cells suggested NK3.3 cells could not readily recycle and lyse 
multiple target cells as well as freshly harvested peripheral NK cells. The study also 
determined that cytotoxic activity was also dependent on culture conditions before 
the assay and that the effector to target (E:T) cell ratio had no effect on cytotoxicity. 
As culture conditions were found to have an effect on NK3.3 lytic activity 
(28), activated and rested cells were cultured in fresh IL-2 media for 24 hours to 
bring all cells up to the same level of activity before separation into activated and 
rested conditions. The "resting" NK3.3 cell condition was used to reproduce 
physiological conditions of peripheral NK cells. 
Experiments were conducted with activated NK3.3 cells to define optimal 
cytotoxic assay conditions and the results are shown in figure 2. NK3.3 cells were 
incubated with radioactively labeled K562 cells for 1.5, 3, and 4.5 hours at effector to 
target ratios of: 6.25:1, 12.5:1, 25:1, and 50:1. The 4.5 hour incubation gave.the 
highest amount of killing at all E:T ratios. However, the 3 hour incubation was 
chosen to examine the effects of genistein on NK3.3 lytic activity because the rate 
of killing appeared to slow between the 3 and 4.5 hour incubation times. The E:T 
(50:1) ratio also was chosen to use as it gave killing> 20%. It was found that rested 
NK3.3 cells did not yield significant cytotoxicity to evaluate optimal conditions. 
Therefore, the parameters established for activated cells were used for all other 
chromium release experiments performed with both activated and rested NK3.3 
cells. 
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Figure 2. Activated NK3.3 cell lysis of K562 target cells at E:T ratios of 6:25 - 50:1 and incubation for 1.5, 3, 
and 4.5 hours. The graph represents the average of 4 chromium release assays for each incubation time/period. 
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Effects of IL-2 on rested NK3.3 cells 
To determine if lytic function could be restored to rested NK3.3 cells, NK3.3 
cells were incubated with IL-2 for 10 and 30 minutes prior to and during a 3-hour 
incubation with target cells. The results of IL-2 incubation with rested NK3.3 cells are 
shown in figure 3. Statistical analysis determined that incubation time was not a 
significant factor. IL-2 at 5 IU was not significantly different from 10 and 15 IU but 
significantly different from 0 (p< .001) and 2.5 IU (p< .035). This IL-2 concentration 
was used in conjunction with genistein for further lytic assays with rested NK3.3 cells 
because it was the lowest dose that gave the greatest increase in lytic activity. 
Genistein's effects on lytic activity of activated and rested NK3.3 cells 
To determine the direct effects of genistein on natural killer cells, activated and 
rested NK3.3 cells were incubated with genistein at concentrations of 0-10 µM for 30 
minutes prior to adding chromium labeled K562 cells. These genistein 
concentrations were chosen because they cover the range of concentrations found 
in the plasma of people who eat soy-containing foods (62). Figure 4 shows the 
average cytotoxicity of activated NK3.3 cells incubated with genistein. Since the 
percent cytotoxicity values varied between chromium release assays but the trend 
remained the same, the baseline cytotoxicity of NK3.3 cells was set at 100% for 
each assay to normalize results. Baseline cytotoxicity for activated NK3.3 cells 
varied between 34.85% and 45.67%. Enhanced cytotoxicity of activated NK3.3 cells 
was observed at concentrations of 0.25 µM to 10 µM of genistein showing a 
significant effect of genistein compared to baseline killing (p< .002). The 0.1 µM 
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Figure 3. Rested NK3.3 cell lysis after incubation with IL-2. Rested NK3.3 cells were stimulated with IL-2 for either 
10 or 30 minutes prior to a 3-hour incubation with K562 targets. Lytic function was enhanced when compared to 
baseline activity. Incubation time was found not to be a significant factor. IL-2 concentration at 5 IU (p < .013) was 
found to be the lowest dose that gave the greatest increase in lytic activity. 
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Figure 4. Genistein enhancement of activated NK3.3 lysis of K562 targets at a 50:1 ratio. Activated NK3.3 cells 
were stimulated with genistein 30 minutes prior to a 3-hour incubation with K562 targets. Baseline activity was set at 
100% and experimental data was calculated relative to this control. Concentrations of 0.25 to 10.0 µM genistein show 
an enhancement of lytic activity (p< .002). The graph represents an average. of 4 chromium release assays. 
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concentration is not significantly different from baseline. But all other concentrations 
demonstrated significant enhancement compared to baseline (0) and (p< .02). 
Figure 5 shows the average cytotoxicity for 4 experiments in which rested NK3.3 
cells were incubated with genistein (Fig. 5A) or genistein plus IL-2 (5 IU/well; Fig. 
5B). The baseline was set at 100% to normalize results. Baseline cytotoxicity for 
rested NK3.3 cells varied between 2.14 and 15.38%. Overall analysis of the effects 
of genistein and IL-2 showed significant enhancement by IL-2 across all genistein 
concentrations (p< .0001). There was marginally significant interaction of genistein 
and IL-2 (p< .095). This interaction indicates that genistein has a different effect on 
rested NK3.3 cells with or without IL-2. 
Rested NK3.3 cells incubated with genistein in the absence of IL-2 demonstrated 
enhanced cytotoxicity at concentrations of 1 to 10 µM of genistein with a range of 4 
to 13%. Statistical analysis demonstrated a significant linear effect of genistein on 
enhancement of cytotoxicity. Specifically, genistein at concentrations of 1 to 10 µM 
enhanced cytotoxicity over the concentrations Oto 0.1 µM. There was no significant 
difference between samples incubated with 0.01 to 0.1 µM. 
Incubation with IL-2 increased cytotoxicity of rested NK3.3 cells by ~350% over 
baseline. However, rested NK3.3 cells stimulated with genistein and IL-2 showed 
significantly less cytotoxicity across all concentrations in comparison with NK3.3 
cells incubated with IL-2 alone (p< .007). Thus, genistein inhibits IL-2 activation of 
resting NK3.3 cells. 
Therefore, genistein alone is able to enhance cytotoxicity of activated and rested 
NK3.3 cells but inhibits the activation of rested NK3.3 cells by IL-2. 
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Figure 5. Rested NK3.3 treated with genistein (A) or with genistein and IL-2 (8). 
Lysis of K562 targets at a 50:1 ratio was enhanced at concentrations of 1 to 
10 µM (p< .0076). The graph represents the average of 4 chromium release assays. 
Cytotoxicity of rested NK3.3 cells without genistein or IL-2 was set at 100% and 
experimental data was calculated relative to this control (A). Lysis of K562 targets at 
a 50:1 ratio was inhibited across all concentrations of genistein in comparison to IL-2 
control cells (0 genistein) (p< .0068). The graph represents the average of 4 
chromium release assays. Cytotoxicity was calculated relative to the 100% 
cytotoxicity established for rested NK3.3 cells without genistein or IL-2 (8). 
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Flow Cytometry 
Quantitation of Intracellular Phosphotyrosine 
Activation of NK cell cytotoxicity is dependent on tyrosine phosphorylation (20). 
Intracellular phosphorylated tyrosine residues can be stained by antibody conjugated 
with fluorescent dye and then analyzed by flow cytometry. The level of tyrosine 
phosphorylation is the resultant balance between phosphorylation by tyrosine 
kinases and dephosphorylation by tyrosine phosphatases. Specific inhibitors of 
these enzymes can experimentally regulate intracellular tyrosine phosphorylation 
levels of NK3.3 cells. Vanadate, a tyrosine phosphatase inhibitor, and staurosporine 
A, a protein tyrosine kinase inhibitor, were used to modulate tyrosine 
phosphorylation levels in N-K3.3 cells. 
These modulators allowed for amplification and inhibition of intracellular 
phosphotyrosine levels and allowed for a comparison to be made on intracellular 
phosphotyrosine levels of NK3.3 cells stimulated with genistein. Vanadate (200 µM) 
and staurosporine A (200 nM) also served as positive and negative controls for flow 
cytometry. Figure 6 is a histogram demonstrating the extent to which these 
modulators regulate phosphotyrosine levels of NK3.3 cells in comparison to baseline 
phosphorylation. 
Vanadate or staurosporine A was incubated with rested and activated NK3.3 
cells to alter intracellular phosphotyrosine levels prior to analysis by flow cytometry. 
Figures 7 A and 78 demonstrates the mean fluorescence intensity of cells labeled 
with fluorochrome tagged anti-phosphotyrosine antibody after incubation with 
vanadate or staurosporine A. Statistical analysjsfor vanadate showed a signigicant 
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. Figure 6. A comparison of intracellular phosphotyrosine levels of NK3.3 cells incubated with and without 
vanadate and staurosporine A. The histogram displayed demonstrates the mean fluorescence intensity of NK3.3 
cells stained with FITC conjugated anti-phosphotyrosine antibody. NK3.3 cells were treated with 200 µM of vanadate 
(green), 200 nM of staurosporine A (red), or control media (baseline, blue) and analysed by flow cytometry for 
intracellular phosphotyrosine levels. 
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Figure 7. lntracetlular phosphotyrosine levels of rested and activated NK3.3 
cells stimulated with vanadate (A) or suppressed with staurosporine A (B). 
Intracellular phosphotyrosine levels are increased by incubation with 50 µM and 200 
µM concentrations of vanadate in contrast to levels seen with 0 µM/baseline 
(p < .001) (A). Intracellular phosphotyrosine levels are decreased upon exposure to 
200 nM of staurosporine A in comparison to levels observed at 0 µM/baseline 
(p< .001) Staurosporine A suppressed activated NK3.3 cells to a greater degree 
than rested cells (p< .003) (B). 
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difference between concentrations (p< .001) and between rested and activated 
NK3.3 cells (p< .003). Statistical analysis showed a significant difference between 
baseline and suppression by staurosporine A (p< .001), between rested and 
activated NK3.3 cells (p< .001), and that staurosporine A suppressed activated 
NK3.3 cells to a greater degree than rested (p< .003). Mean fluorescent intensity 
was used rather than percent positive because stained cell populations shifted up or 
down (as seen in figure 6) rather than separating into distinct populations. 
Intracellular phosphotyrosine levels of activated NK3.3 cells with genistein 
To determine if there was a correlation between the concentrations of genistein 
that enhanced lytic activity and intracellular phosphotyrosine levels, flow cytometry 
analysis was performed on activated NK3.3 cells after a 10-minute incubation with 
genistein or genistein plus vanadate (50 µM). Incubation in the presence of vanadate 
was done to amplify any changes in tyrosine phosphorylation due to incubation with 
the low doses of genistein. (Vanadate at 50µM was used as it was found to be the 
concentration for optimal amplification as shown in figure 7). Figure 8 shows the 
mean fluorescent intensity of activated NK3.3 cells stained for intracellular 
phosphotyrosine after incubation in the presence or absence of vanadate and 
genistein concentrations in a range of Oto 10 µM. Genistein was seen to suppress 
intracellular phosphotyrosine levels across all concentrations (p < .002). There was 
no difference in suppression among the samples incubated with genistein. Vanadate 
enhanced tyrosine phosphorylation across all concentrations of genistein (p< .003). 
However, there was no significant interaction of genistein and vanadate indicating 
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Figure 8. Intracellular phosphotyrosine levels of activated NK3.3 cells incubated with genistein and genistein 
plus 50µM of vanadate. Activated NK3.3 cells were incubated for 10 minutes with either genistein or genistein plus 
vanadate prior to staining with FITC-conjugated antiphosphotyrosine antibody for flow cyotometry analysis. Genistein 
across all concentrations suppressed intracellular phosphotyrosine levels, even with the presence of 50 µM vanadate 
(p < .002). Vanadate enhanced intracellular tyrosine phophorylation (p < .003). There was no significant interaction 
between genistein and vanadate. 
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that the amount of suppression due to genistein was the same in samples with or 
without vanadate. In addition, this data supports the premise that vanadate can 
amplify changes in tyrosine phosphorylation without affecting the trend of the effect. 
Intracellular phosphotyrosine levels of rested NK3.3 cells with genistein 
To see if there was a difference between activated and rested intracellular 
phosphotyrosine levels, rested NK3.3 cells were incubated with genistein or 
genistein plus vanadate (50 µM) for 10 minutes prior to staining and flow cytometric 
analysis. Figure 9 shows that in the case of rested NK3.3 cells genistein 
significantly enhanced intracellular phosphotyrosine levels (p< .003). Vanadate 
increased the levels of intracellular phosphotyrosine (p<. 0001). LSD (least 
significant difference) comparison of means demonstrated that intracellular 
phosphotyrosine levels were enhanced across all concentrations of genistein in 
comparison to baseline (p <. 05). However, there was no significant interaction of 
genistein and vanadate. This indicates that vanadate amplified the effects of 
genistein on intracellular phosphotyrosine, which made the effects of genistein 
easier to observe. 
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Figure 9. Intracellular phosphotyrosine levels of rested NK3.3 cells incubated with genistein and genistein 
plus SOµM of vanadate. Rested NK3.3 cells were incubated for 10 minutes with either genistein or genistein plus 
vanadate prior to staining with FITC-conjugated phosphotyrosine antibody for flow cytometry analysis. Genistein 
significantly enhanced intracellular phosphotyrosine levels across all concentrations (p< .005). This enhancement was 
also observed when tyrosine phosphorylation was amplified with vanadate. 
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DISCUSSION 
Our studies with NK cells isolated from human peripheral blood showed 
enhancement of lytic activity in the presence of low doses of genistein and daidzein. 
This enhancement was observed specifically at concentrations of 0.1 µM to 0.5 µM 
with lytic activity 40% higher than baseline cytotoxicity. This is the first time that 
daidzein has been shown to enhance lytic activity like genistein. 
Genistein was studied because a great deal of literature has been written about it 
being a PTK inhibitor. We were interested to see if this enhancement of lytic activity 
was linked to tyrosine phosphorylation. 
It was unclear from these results if genistein was having a direct or indirect effect 
on peripheral blood NK cells. Thus, a pure NK cell population was needed to 
examine the direct effects of genistein on cytotoxicity and intracellular 
phosphotyrosine. The NK3.3 cell line was used to answer these questions. 
The NK3.3 cell line solved the problems of lack of quantity and a pure cell 
population. However, it is a cloned cell line, which means differences could exist 
from NK cells harvested from fresh peripheral blood leukocytes. NK3.3 cell growth is 
dependent on the continued presence of IL-2. This is not known about the 
physiological environment for peripheral NK cells. IL-2 in the media maintains the 
lytic activity of NK3.3 cells but peripheral NK cells are also constitutively active. 
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Genistein enhances lytic activity of peripheral blood NK cells in the presence and 
absence of IL-2 (68). 
This research sought to correlate the enhancement of NK3.3 cytotoxicity as 
determined by chromium release assays by low doses of genistein with changes in 
protein tyrosine kinase activity determined by flow cytometry analysis of intracellular 
phosphotyrosine residues. In the case of activated NK3.3 cells, genistein increased 
cytotoxicity but suppressed intracellular phosphotyrosine levels in parallel samples. 
However, with rested NK3.3 cells a correlation was observed between genistein 
enhancement of cytotoxicity and intracellular phosphotyrosine at the higher 
concentrations tested (0.25,... 10 µM). 
Genistein was observed to enhance cytotoxicity of activated NK3.3 cells at 
concentrations of 0.25 to 10 µM in chromium release assays by~ 14%. This reflects 
a broader range of enhancement of lytic activity then the studies using "NK-rich" cell 
populations of peripheral blood lymphocytes. Those studies demonstrated no 
enhancement at 1 µM and suppression at doses > 5 µM. Genistein was seen to 
suppress phosphorylation of tyrosine residues at all concentrations as detected by 
flow cytometry analysis. This suggests that genistein enhancement of cytotoxicity 
can act through a pathway other than PTKs. 
Experiments using rested NK3.3 cells, which were designed to mimic the 
physiological state of peripheral NK cells harvested from blood, not only showed 
enhancement of cytotoxicity, but also had a corresponding enhancement of 
intracellular phosphotyrosine residues. Genistein at concentrations of 0.25 to 1 0 µM 
enhanced cytotoxicity by ~ 13% as determined by chromium release assays. Again 
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this concentration range differs from that observed with "NK-rich" population studies. 
Genistein was seen to enhance intracellular phosphotyrosine levels of rested NK3.3 
cells across all concentrations. This enhancement was amplified by the presence of 
vanadate. 
Taking all results together, the enhancement of NK3.3 cytotoxicity by genistein 
appears to be acting through a pathway independent of tyrosine phosphorylation. 
Baseline intracellular phosphotyrosine for rested NK3.3 cells is lower than that 
observed for activated NK3.3 cells. The effect of genistein on NK3.3 cell PTK activity 
is clearly dependent on the activation state of the cell. 
Though rested NK3.3 cells could have lytic activity restored by IL-2, genistein 
was found to suppress this effect. The increase in cytotoxicity of rested NK3.3 cells 
due to genistein was less than that when stimulated with IL-2. In addition, incubation 
of rested NK3.3 cells with IL-2 and genistein demonstrated less cytotoxicity than 
incubation with IL-2 alone. This would suggest that genistein enhancement is not 
through the use of IL-2 receptors and/or that it is using a pathway separate from IL-2 
activation. Alternatively, different receptors maybe expressed that genistein can act 
upon depending on the activation state of the cell. 
Genistein at low doses on NK3.3 cells showed an enhancement of lytic activity 
over a broader concentration range than that of "NK-rich" populations. However, this 
lytic activity was not as great as that seen with the "NK-rich" populations, suggesting 
that genistein is also acting upon other cell types in the population, which could lead 
to cross talk between those cells and NK cells. 
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